Assessment and predictive ability of the absolute neutrophil count in peripheral blood for in vivo CAR T cells expansion and CRS

• DOI: 10.1136/jitc-2023-007790
• Publication Date: 2023-11-28T08:11:05Z
• Authors: Man Zhang; Xiaolu Long; Yi Xiao; Jin Jin; Caixia Chen; Jiao Meng; Wanying Liu; Aichun Liu; Liting Chen
• Keywords: Absolute neutrophil count

Chimeric antigen receptor (CAR) T cell therapy is an advanced and effective immunotherapy for relapsed or refractory B-cell malignancies. High expansion of CAR cells in vivo durable antitumor activity indicate a persistent therapeutic response. However, this treatment linked to high frequency adverse events, such as cytokine release syndrome (CRS), which affects its efficacy can even be life-threatening. At present, variety markers associated with clinical response toxicity after infusion have been reported. Although these biomarkers act indicators reflecting well CRS, they fail predict the rate cells. Hence, further investigation urgent find new biomarker fill void. We analyzed association between absolute neutrophil count (ANC) CRS 45 patients malignancies from two trials. proposed that ANC could practical conducted feasibility analysis on predictive ability. In study, 17 hematological malignancy anti-B-cell maturation CAR-treated 28 CAR19/22 T-cell-treated were enrolled divided into ANC-absence group ANC-presence group. The results showed absence correlated positively rate. used marker expansion. Moreover, experienced more severe performed ability CRS. addition, peak serum concentration several cytokines involved was higher absence. Thus, we suggest evaluative during therapy, help maximize efficacy, reduce treatment-related prolong survival.